The EU-TOPIA evaluation tool: An online modelling-based tool for informing breast, cervical, and colorectal cancer screening decisions in Europe.
The EU-TOPIA evaluation tool: An online modelling-based tool for informing breast, cervical, and colorectal cancer screening decisions in Europe.
复制标题
EU-TOPIA评估工具：一种基于在线建模的工具，用于告知欧洲的乳腺癌，宫颈癌和结直肠癌筛查决策。
DOI：
10.1016/j.pmedr.2021.101392
复制
发表时间：
2021-06
影响因子：
2.8
通讯作者：
EU-TOPIA consortium
中科院分区：
文献类型：
--
作者：
Gini A;van Ravesteyn NT;Jansen EEL;Heijnsdijk EAM;Senore C;Anttila A;Novak Mlakar D;Veerus P;Csanádi M;Zielonke N;Heinävaara S;Széles G;Segnan N;de Koning HJ;Lansdorp-Vogelaar I;EU-TOPIA consortium
为了支持欧洲国家改善乳腺癌、宫颈癌和结直肠癌 (CRC) 筛查计划，EU-TOPIA 联盟开发了一种基于微观模拟筛查分析 (MISCAN) 模型的在线用户友好工具（EU-TOPIA 评估工具；https://miscan.eu-topia.org）。我们设计了一个在线平台，允许利益相关者使用其国家特定数据（人口统计、流行病学和癌症筛查信息）来量化其国家不同癌症筛查方案的未来危害和益处。可以模拟当前的癌症筛查计划以及筛查方案潜在变化的影响（例如延长目标年龄或增加筛查出勤率）。结果根据国家特定人群进行调整。为了说明该工具，我们使用该工具模拟了荷兰的两种不同的 CRC 筛查场景：55-75 岁每两年进行一次粪便免疫化学检测 (FIT)，55-75 岁每十年进行一次结肠镜检查。荷兰筛查计划的数据被用来为这两种情况提供信息。在荷兰，估计有 482,700 例 CRC 病例和 178,000 例 CRC 死亡病例通过 FIT 筛查（针对 40-100 岁的个体，2018-2050 年），进行了 4730 万例 FIT（192 万例阳性，其中 164 万人坚持进行诊断性结肠镜检查）。通过结肠镜筛查，CRC 发病率和死亡率分别比当前 FIT 筛查计划低 17% 和 14%，但结肠镜检查需求却高出 7 倍。我们的研究为利益相关者和医学会提供了一个重要的在线工具，用于量化欧洲早期癌症检测的益处和危害的估计。
Aiming to support European countries in improving their breast, cervical, and colorectal cancer (CRC) screening programmes, the EU-TOPIA consortium has developed an online user-friendly tool (the EU-TOPIA evaluation tool; https://miscan.eu-topia.org) based on the Microsimulation Screening Analysis (MISCAN) model. We designed an online platform that allows stakeholders to use their country-specific data (demographic, epidemiological, and cancer screening information) to quantify future harms and benefits of different cancer screening scenarios in their country. Current cancer screening programmes and impacts of potential changes in screening protocols (such as extending target ages or increasing screening attendance) can be simulated. Results are scaled to the country-specific population. To illustrate the tool, we used the tool to simulate two different CRC screening scenarios in the Netherlands: biennial fecal immunochemical testing (FIT) in ages 55–75 and colonoscopy every ten years in ages 55–75. Data from the Dutch screening programme was used to inform both scenarios. A total of 482,700 CRC cases and 178,000 CRC deaths were estimated in the Netherlands with FIT screening (for individuals aged 40–100 years, 2018–2050), with 47.3 million FITs performed (1.92 million positives of which 1.64 million adhered to diagnostic colonoscopy). With colonoscopy screening, CRC incidence and mortality were, respectively, up to 17% and 14% lower than in the current FIT screening programme, requiring, however, a colonoscopy demand that was 7-fold higher. Our study presents an essential online tool for stakeholders and medical societies to quantify estimates of benefits and harms of early cancer detection in Europe.
登录
查看更多内容
影响因子：
2.9
作者：
Csanadi, Marcell;Gini, Andrea;Lansdorp-Vogelaar, Iris
通讯作者：
Lansdorp-Vogelaar, Iris
影响因子：
4.5
作者：
de Carvalho TM;Heijnsdijk EA;de Koning HJ
通讯作者：
de Koning HJ
影响因子：
105.7
作者：
Buskermolen, Maaike;Cenin, Dayna R.;Lansdorp-Vogelaar, Iris
通讯作者：
Lansdorp-Vogelaar, Iris
影响因子：
19.7
作者：
Sankatsing, Valerie D. V.;Juraniec, Karolina;van Ravesteyn, Nicolien T.
通讯作者：
van Ravesteyn, Nicolien T.
影响因子：
5.3
作者：
Tomonaga, Yuki;ten Haaf, Kevin;Puhan, Milo A.
通讯作者：
Puhan, Milo A.